Community/Retail

The Committees voted 12 to 5 that the drug should be labeled as an abuse-deterrent product by the nasal route of abuse, but they voted 10 to 7 that the drug should not be labeled as an abuse-deterrent product by the intravenous route of abuse.

Officials with the FDA noted that patients are sometimes being treated with medications that are not approved (including compounded medicines as well as hydromorphone, bupivacaine, fentanyl and clonidine) for use with an intrathecal implanted pump.

The AMA and CDC are working with their local offices, affiliates, and partners to promote and activate the campaign in their communities, with evidence-based materials to aid physicians and other health care providers in the screening, diagnosis and treatment process.

The FDA has accepted Genentech’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.

In this clip, Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist and Associate Professor at The Ohio State University, tells Pharmacy Times about One Health, a movement dedicated to bringing together different fields that handle antibiotics to prevent the misuse of these bacteria-killing drugs.

On Wednesday, October 24, and Saturday, October 27, student pharmacists from the University of Maryland School of Pharmacy chapter of the APhA-ASP joined forces with the University of Maryland, Baltimore Police and the Drug Enforcement Administration (DEA) to host our bi-annual Drug Take-Back Day at the University’s SMC Campus Center.